Savara (SVRA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.15
- Surprise
- —
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; Eu — benzinga, 2026-08-11
- Savara Q2 EPS $(0.16) Misses $(0.14) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates SVRA Sell at 4.9/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -11.4%), Material insider selling (5 sells, 0.06% of cap)
- Momentum score 2.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.39
- Price target
- $9.52
- Stop
- $4.99
- Upside to target
- +76.6%
- Reward-to-risk
- 10.8:1
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
SVRA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.10B
- P/E (fwd)
- -17.2
- 52-week range
- $3.34–$7.00
- Off 52-week high
- 23.1%
- RSI (14)
- 50
- Volume vs avg
- 0.42×
- Score today
- 4.9/10